Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which has completed Phase 1a and Phase 1b clinical trials for use in patients with mild to moderate Alzheimer's disease. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryHealth Care Technology
SectorMedical
Phone415-910-5717
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees16
Next Earnings DateN/A
OptionableNot Optionable
Cortexyme (NASDAQ:CRTX) Frequently Asked Questions
What is Cortexyme's stock symbol?
Cortexyme trades on the NASDAQ under the ticker symbol "CRTX."
What price target have analysts set for CRTX?
3 analysts have issued 1-year target prices for Cortexyme's stock. Their forecasts range from $14.00 to $53.00. On average, they anticipate Cortexyme's stock price to reach $34.25 in the next twelve months. This suggests a possible upside of 26.9% from the stock's current price. View Analyst Price Targets for Cortexyme.
What is the consensus analysts' recommendation for Cortexyme?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cortexyme in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cortexyme.
Has Cortexyme been receiving favorable news coverage?
News articles about CRTX stock have been trending negative recently, according to InfoTrie. The research firm rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Cortexyme earned a news sentiment score of -2.3 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Cortexyme.
Who are some of Cortexyme's key competitors?
Some companies that are related to Cortexyme include Crispr Therapeutics (CRSP), Iovance Biotherapeutics (IOVA), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Audentes Therapeutics (BOLD), Regenxbio (RGNX), Coherus Biosciences (CHRS), Sangamo Therapeutics (SGMO), Editas Medicine (EDIT), Orchard Therapeutics (ORTX), Momenta Pharmaceuticals (MNTA), Fate Therapeutics (FATE), Aerie Pharmaceuticals (AERI) and Alector (ALEC).
What other stocks do shareholders of Cortexyme own?
Who are Cortexyme's key executives?
Cortexyme's management team includes the folowing people:
- Ms. Casey C. Lynch, Co-Founder, Chairman, Pres & CEO (Age 45)
- Mr. Stephen S. Dominy, Co-Founder, Chief Scientific Officer & Director (Age 63)
- Ms. Kristen Gafric, Co-Founder, Sr. VP of Legal & Admin. and Sec. (Age 43)
- Mr. Christopher P. Lowe, CFO & Treasurer (Age 48)
- Dr. Michael J. Detke, Chief Medical Officer (Age 52)
When did Cortexyme IPO?
(CRTX) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 4,400,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.
When does Cortexyme's lock-up period expire?
Cortexyme's lock-up period expires on Tuesday, November 5th. Cortexyme had issued 4,412,000 shares in its initial public offering on May 9th. The total size of the offering was $75,004,000 based on an initial share price of $17.00. After the expiration of Cortexyme's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.
Who are Cortexyme's major shareholders?
Cortexyme's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (0.65%), BlackRock Inc. (0.52%), Morgan Stanley (0.17%), Charles Schwab Investment Management Inc. (0.09%), Northern Trust Corp (0.09%) and Landscape Capital Management L.L.C. (0.05%). View Institutional Ownership Trends for Cortexyme.
Which major investors are buying Cortexyme stock?
CRTX stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., BlackRock Inc., Morgan Stanley, Charles Schwab Investment Management Inc., Northern Trust Corp, Landscape Capital Management L.L.C., Bank of New York Mellon Corp and Wells Fargo & Company MN. View Insider Buying and Selling for Cortexyme.
How do I buy shares of Cortexyme?
Shares of CRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cortexyme's stock price today?
One share of CRTX stock can currently be purchased for approximately $26.98.
How big of a company is Cortexyme?
What is Cortexyme's official website?
How can I contact Cortexyme?
Cortexyme's mailing address is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 415-910-5717 or via email at [email protected]
MarketBeat Community Rating for Cortexyme (NASDAQ CRTX)
MarketBeat's community ratings are surveys of what our community members think about Cortexyme and other stocks. Vote "Outperform" if you believe CRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
